Laurus Labs has informed that US Food and Drug Administration (USFDA) has completed inspection of API facilities in Unit 1 and 3 in Parawada, Visakhapatnam, Andhra Pradesh, with two observations. This is a regular surveillance audit by USFDA, and the observations are procedural in nature and no data integrity issues were observed.
The above information is a part of company’s filings submitted to BSE.